A Caffeine Byproduct Is Now Sold on Its Own

A compound that most people have never consciously ingested on its own, despite consuming it almost every time they drink coffee, is now showing up as a standalone supplement ingredient in 2026. Paraxanthine, chemically known as 1,7-dimethylxanthine, is not a new discovery. It is the primary metabolite the human body produces when it breaks down caffeine, and it has existed inside every cup of coffee ever consumed. What has changed is that manufacturers can now isolate it and sell it directly, without the caffeine attached.

According to the 2023 review "Paraxanthine safety and comparison to caffeine," published in the National Library of Medicine's PMC archive, roughly 70 to 72 percent of ingested caffeine converts into paraxanthine inside the body. The same review reports that paraxanthine has a half life of 3.1 hours, compared to 4.1 hours for caffeine, and that its total plasma clearance is greater. In practical terms, it moves through the body faster and exits sooner than the caffeine that produced it.

That distinction has become the basis of a small but growing supplement category. Formulators are now selling paraxanthine as a finished product rather than as a footnote in caffeine metabolism research, marketing it as a way to access the alertness associated with caffeine while sidestepping the jitters, anxiety and crash that caffeine itself can cause.

What Is Paraxanthine and Why Is It Different From Caffeine?

Paraxanthine is the compound the liver produces after processing caffeine, and it does much of the receptor work that people typically credit to caffeine directly. The liver enzyme CYP1A2 performs that demethylation, and CYP1A2 activity varies widely from person to person, which is a documented reason two people can drink the same cup of coffee and feel very different effects.

Both caffeine and paraxanthine act as adenosine receptor antagonists, meaning they block the receptors responsible for signaling fatigue to the brain. Paraxanthine shows higher binding potency at the A1 and A2a receptors than caffeine does. Because it is already the downstream product of caffeine metabolism, a person consuming paraxanthine directly does not have to wait on their own CYP1A2 activity to convert it, and its faster clearance means it does not linger in the system the way caffeine can.

Paraxanthine is not synthetic or invented in a lab. It occurs naturally in small amounts in several plants, including:

• Green coffee beans
• The cotyledonary leaves of Coffea arabica
• Theobroma cacao fruits
• Roasted coffee beans
• Citrus flowers
• Sicilian orange flower honey

The Conversation published a 2026 explainer on paraxanthine's appearance in coffee and energy drinks, describing how the compound has moved from a metabolic curiosity into an ingredient brands now formulate around directly.

How Are Companies Turning a Metabolite Into a Consumer Product?

They are isolating it and dosing it precisely, the same way any single ingredient supplement is built, rather than leaving it as a byproduct inside a caffeine drink. One entrant is Parachew, a caffeine free energy gummy brand based in Scottsdale, Arizona, made by McAb Nutraceuticals, LLC, dosed at 200 mg of paraxanthine per gummy, sold 30 gummies to a jar in Caramel Coffee and Strawberry Lemonade flavors. The label sets a daily maximum of 400 mg, or two gummies.

Turning a bitter metabolite into something people would choose to eat twice a day was not simple. Noah McCashland, founder of McAb Nutraceuticals, said the formulation process required extensive trial and error before the product was viable. "Paraxanthine has a bitterness that is hard to mask at a real dose," McCashland said. "Five or six labs took a run at this before one of them found a formulation that could hold a full 200 milligrams in a gummy and still taste like something you'd want to eat again the next day."

Getting the taste right mattered because the dose itself was non negotiable. A gummy that hid a smaller amount of paraxanthine behind a pleasant flavor would not deliver the same effect the research describes, so the formulation work had to solve for palatability without cutting the active dose. That is what pushed the project through repeated attempts at multiple labs rather than settling early.

Consumers interested in trying the format can find Parachew's paraxanthine gummy sold direct to consumer at parachew.com, with shipping currently limited to addresses within the United States.

Does the Research Support Paraxanthine as an Energy Ingredient?

The human safety and pharmacology data is more established than the performance data, but both point in a similar direction. The 2023 PMC review is the primary human reference point for paraxanthine's comparative pharmacology, covering its metabolism, clearance and receptor activity relative to caffeine. That review is what underlies most of the specific numbers now appearing on supplement marketing, including the 70 to 72 percent conversion rate and the half life comparison.

Animal research adds an early signal beyond alertness alone. A 2022 study published in the PMC archive, titled "Paraxanthine Supplementation Increases Muscle Mass, Strength, and Endurance in Mice," reported measurable performance effects in rodent models. Translating rodent dosing directly to a human consumer product is a separate scientific question, and researchers have not yet settled it, but the finding has added to interest in paraxanthine beyond simple wakefulness.

The side by side comparison below draws on the 2023 PMC review for the pharmacological figures:

What Comes Next for Paraxanthine as an Ingredient Category?

More products naming the compound directly on the label, rather than burying it inside a caffeine blend, appears to be the near term trajectory in 2026. Because paraxanthine is already the compound responsible for much of caffeine's receptor activity, brands marketing it as a standalone ingredient are positioning it as a way to access that effect without the variability that comes from individual CYP1A2 metabolism rates, and without the jitters, anxiety or crash that are associated with caffeine itself rather than with paraxanthine.

The science describing paraxanthine's pharmacology is not new. What is new is the willingness of manufacturers to sell it as the finished product instead of an intermediate step in caffeine's breakdown, dosed at a stated number of milligrams with a printed daily maximum. As more entrants test the format, particularly in categories like gummies where a two piece maximum is something a consumer can visually count rather than measure, the compound is likely to keep moving further from academic journals and further onto ordinary store shelves.